After that, they designed a series of cambinol analogues and discovered the SIRT3 selective inhibitor 4- [(2-Hydroxy-6-phenylnaphthalen-1-yl) methyl]-5-(4-methylphenyl) -2, 3-dihydro-1H-pyrazol-3-one (SIRT3 IC50 = 6 μM) that has good anti-cancer potential 190. Here, SIRT3 is linked to cancer.